<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030355</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069158</org_study_id>
    <secondary_id>CHEMGENEX-CGX-635-APL-101</secondary_id>
    <secondary_id>MDA-DM-01265</secondary_id>
    <nct_id>NCT00030355</nct_id>
  </id_info>
  <brief_title>Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia</brief_title>
  <official_title>A Phase I/II Open-Label Study Of The Intravenous Administration Of Homoharringtonine (CGX-635) Salvage Therapy For The Treatment Of Refractory Acute Promyelocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of homoharringtonine in treating&#xD;
      patients who have refractory acute promyelocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of salvage therapy comprising homoharringtonine in patients with&#xD;
           refractory acute promyelocytic leukemia.&#xD;
&#xD;
        -  Determine the antileukemic efficacy of this drug in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive remission induction therapy comprising homoharringtonine (HH) IV&#xD;
      continuously on days 1-14. Courses repeat every 4 weeks in the absence of unacceptable&#xD;
      toxicity until a complete remission (CR) is achieved or the patient fails to respond after 3&#xD;
      courses.&#xD;
&#xD;
      Patients who achieve a CR during induction therapy receive maintenance therapy comprising HH&#xD;
      IV continuously on days 1-7. Maintenance treatment repeats every 4 weeks for a total of 12&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety by physical examinations, vital signs, laboratory studies (routine hematology, clinical chemistry, pharmacokinetics, urinalysis, chest x-ray, and EKG), and solicited and unsolicited adverse events</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy by response to treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>homoharringtonine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of acute promyelocytic leukemia confirmed morphologically and by t(15;17)&#xD;
             translocation or molecular polymerase chain reaction&#xD;
&#xD;
          -  Refractory to tretinoin, anthracyclines, and arsenic-based therapy (including arsenic&#xD;
             trioxide) and for which no other alternative therapy of higher priority is appropriate&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  12 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-3&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 4 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  ALT no greater than 3 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No active ischemia&#xD;
&#xD;
          -  No other uncontrolled cardiac condition (e.g., angina pectoris, cardiac arrhythmia,&#xD;
             hypertension, or congestive heart failure)&#xD;
&#xD;
          -  No myocardial infarction within the past 12 weeks&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent illness that would preclude study&#xD;
&#xD;
          -  No other active malignancy&#xD;
&#xD;
          -  No uncontrolled active infection&#xD;
&#xD;
          -  No clinically significant screening serum chemistry results unless attributed to acute&#xD;
             promyelocytic leukemia&#xD;
&#xD;
          -  No medical or psychiatric condition that would preclude informed consent or study&#xD;
             therapy&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  HTLV-I and HTLV-II negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior or concurrent leukapheresis allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 15 days since prior systemic chemotherapy unless leukemia progression&#xD;
             necessitates early therapy&#xD;
&#xD;
          -  No other concurrent systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 15 days since other prior antileukemic therapy unless leukemia progression&#xD;
             necessitates early therapy&#xD;
&#xD;
          -  No other concurrent antileukemic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Cortes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 21, 2013</last_update_submitted>
  <last_update_submitted_qc>March 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2013</last_update_posted>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Homoharringtonine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

